Market News & Trends
Biological Therapies in Cancer Treatment to Reach $66 Billion in 2019
BCC Research reveals in its new report on biologic cancer treatment that access and affordability of cancer treatment options in various countries, along with a…
NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma
LAGUNA HILLS, CA, February 9, 2015 – NanoSmart® Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from…
Melinta Therapeutics Secures $30 Million From Hercules Technology Growth Capital
Melinta Therapeutics recently announced it has entered into a $30-million growth capital debt financing agreement with Hercules Technology Growth Capital, Inc. The initial funding of…
Consort Medical Signs Supply Agreement for Integrated Dose Counter
Consort Medical plc recently announced the conclusion of a significant new commercial supply agreement for its proprietary integrated dose counter (IDC) system. The multi-year supply…
FDA Approves Genentech’s Lucentis (Ranibizumab Injection)
Genentech, a member of the Roche Group, recently announced that the US FDA approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR) in…
Achillion Achieves 100% SVR12 In Phase II Trial
Achillion Pharmaceuticals, Inc. recently announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase II study to evaluate the efficacy, safety, and tolerability of 6…
Strategic Science & Technologies Initiates Phase I Study to Evaluate Topical Sildenafil
Strategic Science & Technologies recently announced the initiation of a Phase I trial of SST-6006, a first-in-class topical sildenafil product candidate in development for the…
La Jolla Pharmaceutical Company Announces Special Protocol Assessment For Planned Phase III Trial
La Jolla Pharmaceutical Company recently announced it has reached agreement with the US FDA on a Special Protocol Assesment (SPA) for its Phase III clinical…
GlaxoSmithKline Encounters Initial Resistance Following Directional Shift
Following a less than flattering financial performance in 2014, GlaxoSmithKline plc (GSK) is realigning its operating structure with its corporate objectives and cashing in on…
Technological Breakthroughs Aiding the Biologics Market
BCC Research reveals in its new report on biologic therapeutic drugs, the biologics or biopharmaceutical therapeutic market holds important implications for the future of medicine…
HER2-Negative Breast Cancer Treatment Market Value to Reach $6.12 Billion
The market value for HER2-negative breast cancer therapeutics will increase more than fourfold, from $1.45 billion in 2013 to an estimated $6.12 billion by 2023,…
Pluristem Announces Significant New Findings From Muscle Injury Trial
Pluristem Therapeutics Inc. recently announced an important new finding from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle…
Sanofi & MannKind Announce Afrezza, the Only Inhaled Insulin, Now Available in the US
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies…
Lysosomal Therapeutics Raises $20 Million
Lysosomal Therapeutics Inc. recently announced it has raised $20 million in Series A financing. This internal round consisted of expanded funding commitments from its existing…
Breakthrough Brings 3M One Step Closer to Introducing New Alternative Drug Delivery Method
Getting an injection at the doctor’s office typically does not rank high on many people’s wish list. Due to 3M scientists’ know-how, the day is…
InSite Vision Announces License Agreement
InSite Vision Incorporated recently announced that it has entered into a license agreement with Nicox S.A., a France-based publicly traded company, for the development and…
ICON to Acquire MediMedia Pharma Solutions
ICON plc recently announced it has agreed, subject to certain customary closing conditions, to acquire MediMedia Pharma Solutions for a cash consideration of $120 million.…
Intercept Receives Breakthrough Therapy Designation
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), recently announced that its investigational product obeticholic acid (OCA) has received "breakthrough therapy designation" from the US FDA for the…
Global Market for Intravenous Therapy & Vein Access to Reach $27.2 Billion in 2019
BCC Research anticipates that increasing competition, patent expirations, and evolving customer needs will influence research and development (R&D) spending in the intravenous (IV) therapy and…
Continuous Glucose Monitoring Market Surging at 19.6% CAGR; R&D Soon to Create Devices for Faster Administration
BCC Research (www.bccresearch.com) reveals in its new report on continuous glucose monitoring (CGM), the total CGM market is forecast to reach a value of at…
